HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reeder, C. E. Search for Related Content PubMed PubMed Citation Articles by Reeder, C. E.

C. EEEDERREEDER, PH.D., is Professor of Pharmacoeconomics Outcomes Research and Evaluation, College of Pharmacy, University of South Carolina, Room 109, Coker Life Sciences Building, 715 Sumter Street, Columbia, SC 28208 (reeder{at}cop.sc.edu).

Purpose. The elements and limitations of pharmacoeconomic models, types of analytic methods used in pharmacoeconomic evaluations, outcomes used in studies of anemia treatments, and comparative efficacy and cost-effectiveness of the two available erythropoietic therapies in the treatment of anemia in cancer and critical care patients are discussed. Summary. Clinical, humanistic, and economic outcomes should be taken into consideration in pharmacoeconomic models. The validity of such models may be compromised by a lack of outcome data, unreasonable assumptions, the heterogeneity of the patient population, patient selection bias in comparative studies, and inconsistent use of instruments to measure outcomes. The degree of anemia in patients with cancer correlates with health-related quality of life (QOL). Erythropoietic therapy increases hemoglobin concentrations and QOL, reduces the need for blood transfusions, and is cost-effective for treating anemia in cancer and critical care patients. Epoetin alfa may provide a more rapid hemoglobin response and improvement in QOL at a lower cost than darbepoetin alfa. Front loading with weekly doses of either erythropoietic agent followed by a three-week-long dosing interval for maintenance treatment may be used to quickly correct anemia, improve convenience, and reduce costs. Conclusion. Erythropoietic therapy for the treatment of anemia in cancer and critical care patients is cost-effective. Index terms: Anemia; Blood; Costs; Critical illness; Darbepoetin alfa; Dosage schedules; Drug comparisons; Epoetin alfa; Hematopoietic agents; Methodology; Models; Neoplasms; Outcomes; Pharmacoeconomics; Quality of life

 

This article has been cited by other articles:

				M. W. Kruse and J. L. Lee Questionable conclusions about epoetin alfa Am. J. Health Syst. Pharm., September 1, 2007; 64(17): 1789 - 1791. [Full Text] [PDF]